How do you approach myeloablative chemotherapy for high-risk Ewing sarcoma patients?  

This question has been discussed and debated in the literature for many years. This is largely due to the lack of prospective randomized trials to properly answer the question. Even when studied in this manner, the variable definition of high-risk and study design has made establishing generalizable...